Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2019
Trust Is the Key Ingredient in Medicaid Value-Based Contracts, Manufacturers and Payers Agree
March 26, 2019
Keeping an Eye on Increasing Competition in the Specialty Drug Pipeline
March 27, 2019
Dr Sebastian Schneeweiss on How Rapid-Cycle Analytics Can Identify High-Risk, High-Cost Patients
March 27, 2019
Dr Crescent Moore Outlines Part D Changes to Expect in 2020
March 27, 2019
The Balancing Act of Using Pharmacy Strategies to Fight the Opioid Epidemic
March 27, 2019
Current and Future Status of Drug Pricing Reform as the Blueprint Approaches the 1-Year Mark
March 27, 2019
Dr Steven Pearson: ICER Can Provide More Information When a Drug is Approved With Limited Data
March 28, 2019
Sophie Schmitz on the Importance of Considering Value of Gene Therapies, Not Just Cost
March 28, 2019
Managing Cholesterol With PCSK9 Inhibitors and Overcoming Operational Challenges in Practice
March 28, 2019
Dr James Chambers Discusses Variability in Specialty Drug Coverage and Its Impact
March 29, 2019
Dr Michael Steinman Discusses Effective Strategies for Improving Medication Management
March 29, 2019
Costs of Living With HIV Can Be Mitigated by Rapid Initiation of ART Post Diagnosis
March 29, 2019
Real-Time Prescription Benefit Checks Could Provide Accurate Cost Estimates at the Point of Prescribing
April 01, 2019
Dr Brian MacDonald Explains How Technology Can Improve Patient Management Strategies
April 10, 2019
Dr Crescent Moore on the Effect of Step Therapy in MA Plans, Other Formulary Regulations
April 13, 2019
Dr Michael Steinman on the Importance of Medication Management Strategies for Older Adults
April 15, 2019
Currently Reading
Dr Sebastian Schneeweiss: How Payers Can Benefit From Rapid-Cycle Analytics of Real-World Evidence
April 19, 2019
Dr Sebastian Schneeweiss Discusses How Rapid-Cycle Analytics Can Evaluate Drug Safety, Efficacy
May 01, 2019
Dr Michael Steinman Details Opportunities for Improving Medication Management Strategies
May 05, 2019
Dr Crescent Moore Outlines CMS' Efforts to Address the Opioid Epidemic
May 13, 2019
Dr Sebastian Schneeweiss: In 5 Years, Rapid-Cycle Analytics Will Account for Majority of Analyses
May 15, 2019
Dr Jane Barlow on Innovations, Limitations Within Alternative Payment Models
January 14, 2020

Dr Sebastian Schneeweiss: How Payers Can Benefit From Rapid-Cycle Analytics of Real-World Evidence

Using rapid-cycle analytics of real-world evidence, we can get patients on the most appropriate medications and also implement medication adherence interventions, explained Sebastian Schneeweiss, MD, ScD, professor of medicine and epidemiology, Harvard Medical School and Brigham and Women's Hospital, and co-founder of Aetion.


Using rapid-cycle analytics of real-world evidence, we can get patients on the most appropriate medications and also implement medication adherence interventions, explained Sebastian Schneeweiss, MD, ScD, professor of medicine and epidemiology, Harvard Medical School and Brigham and Women's Hospital, and co-founder of Aetion.

Transcript

One high-risk, high-cost patients are identified by rapid-cycle analytics of real-world evidence, how can this information be used by payers?

So, once we have identified those target patients, we can, working closely with payer organizations, produce lists of these patients. These are scrambled ID numbers; we don’t know the names as the analytics platform, but the payer very much knows the names and can now send out specialists in order to talk to the patients or talk to the providers and say, “You’re on this and that medication. Maybe it is better or maybe you should consider using this or that medication.”

Other interventions are adherence interventions trying to improve adherence. A chronic issue in this country and many other industrialized countries, the patients are not staying on the medications that were prescribed and there are several tools for how we can improve that.

How can rapid cycle analytics of real-world evidence improve patient care and lower costs?

If you truly have a medication that improves health outcomes, what we still see in many situations is that the uptake of that medication is low. This is sometimes because of formulary decision making and this is sometimes because physicians stay with what they’re used to and they don’t want to use newer medications. Some of these new medications are truly efficacious and large randomized trials have shown 20% reductions in hospitalizations, for example.

Nevertheless, they’re not picked up at the pace you would think. Giving health plans the confidence that yes, in their own populations with their own analytics, they can see the benefits, has turned out to be a very powerful tool to change the perception of health plans managers and turning these target populations that will be of high benefit for these medications into more adherent patients into patients using the most efficacious medication.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up